...
首页> 外文期刊>Heart, lung & circulation >Can we repair the mitral valve from outside the heart? A novel extra-cardiac approach to functional mitral regurgitation.
【24h】

Can we repair the mitral valve from outside the heart? A novel extra-cardiac approach to functional mitral regurgitation.

机译:我们可以从心脏外部修复二尖瓣吗?一种新颖的心脏外功能性二尖瓣反流方法。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Functional mitral regurgitation (FMR) is primarily due to abnormalities of the ventricular muscle in the presence of normal mitral leaflets. Present surgical treatment options address the mitral valve annulus and leaflets but not the ventricular muscle. We discuss the evolution of a concept that describes a ventricular solution to this problem, and report preliminary clinical results from the first five subjects implanted with the latest version of this device. METHODS: Evaluation of safety and efficacy of the latest version of the BACE (Basal Annuloplasty of the Cardia Externally) Device was done first in sheep with rapid ventricular pacing to induce severe MR. The BACE Device was implanted around the base of the heart and chambers on the device filled with normal saline through the subcutaneous ports under echocardiogram until there was no evidence of MR. Once MR was effectively reduced, the chest was closed and the animals recovered, with clinical and echocardiographic analysis through six months of follow-up. Human studies were done with in a similar manner, with subjects that were already undergoing concomitant open-chest coronary artery bypass graft (CABG) surgery. Five subjects with ischaemic MR and triple vessel coronary artery disease were first implanted with the BACE Device, applied epicardially on a beating heart without use of cardiopulmonary bypass, before coronary artery bypass grafting was done. RESULTS: In five sheep, epicardial application of the BACE Device effectively reduced mitral regurgitation from Grade 4 to Grade 0, and the effect was sustained through six months despite ongoing pacing. Terminal studies at six months showed no adhesion to the silicone band. All five human subjects were male, NYHA Class III, with LVEF of 20-40%. Epicardial application and adjustment of the BACE Device was performed safely on a beating heart with effective reduction in FMR to grade <1. All five subjects had three bypass grafts. Reduction in MR was sustained for at least six months and there were no unanticipated or device-related adverse events. CONCLUSION: Epicardial application and adjustment of the BACE Device can be performed safely without CPB with effective reduction in MR.
机译:背景:功能性二尖瓣反流(FMR)主要是由于正常二尖瓣小叶存在时心室肌异常所致。当前的外科治疗选择针对二尖瓣环和小叶,但不适用于心室肌。我们讨论了描述此问题的心室解决方案的概念的演变,并报告了植入了该设备最新版本的前五个受试者的初步临床结果。方法:首先在快速起搏的绵羊中进行最新版本的BACE(体外ia门瓣环成形术)装置的安全性和有效性评估,以诱发严重的MR。在超声心动图检查下,将BACE装置通过皮下端口植入充满生理盐水的心脏底部和腔室周围,直到没有MR迹象为止。一旦MR有效降低,就关闭胸部,并通过六个月的临床和超声心动图分析恢复动物。人体研究以类似的方式进行,受试者已经接受了胸腔开放冠状动脉搭桥术(CABG)。在完成冠状动脉搭桥术之前,首先将五名患有缺血性MR和三支冠状动脉疾病的受试者植入BACE装置,在不使用心肺旁路的情况下将其心外膜应用在跳动的心脏上。结果:在五只绵羊中,心外膜应用BACE装置可有效地将二尖瓣反流从4级降低到0级,尽管持续起搏,但效果可维持六个月。六个月的最终研究表明,该硅胶条没有粘附。所有五个人类受试者均为男性,NYHA III级,LVEF为20-40%。在跳动的心脏上安全地进行心外膜应用和BACE设备的调节,并将FMR有效降低至<1级。所有五个受试者均具有三个旁路移植物。 MR至少持续了六个月,并且没有意外或与设备相关的不良事件。结论:无需CPB即可安全地进行BACE装置的心外膜应用和调节,从而有效降低MR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号